Monday brought very disappointing news, as Celldex (NASDAQ:CLDX)
announced that the second interim analysis of the Phase III study of
its lead drug Rintega (rindopepimut) failed to show a survival benefit
relative to the control arm (Temodar). As a result, the company is
stopping the trial and ending further development of what was expected
to be the company's first drug to reach the market.
This is a surprising (if not shocking) result relative to past trial
results that showed a consistent survival advantage for Rintega, but the
data are what they are. Celldex still has a credibly deep pipeline of
immuno-oncology drugs, but it is likely going to take a little while for
investors to get over this disappointment and consider Celldex again as
an investment.
Click here to continue:
Celldex Demonstrates That Cancer Is Hard
No comments:
Post a Comment